{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,8,2]],"date-time":"2026-08-02T05:29:55Z","timestamp":1785648595197,"version":"3.56.0"},"reference-count":44,"publisher":"Elsevier BV","issue":"9","license":[{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/tdm\/userlicense\/1.0\/"},{"start":{"date-parts":[[2010,9,1]],"date-time":"2010-09-01T00:00:00Z","timestamp":1283299200000},"content-version":"tdm","delay-in-days":0,"URL":"https:\/\/www.elsevier.com\/legal\/tdmrep-license"}],"content-domain":{"domain":["dmd.aspetjournals.org","elsevier.com","sciencedirect.com"],"crossmark-restriction":true},"short-container-title":["Drug Metabolism and Disposition"],"published-print":{"date-parts":[[2010,9]]},"DOI":"10.1124\/dmd.110.032268","type":"journal-article","created":{"date-parts":[[2010,6,3]],"date-time":"2010-06-03T06:07:44Z","timestamp":1275545264000},"page":"1499-1504","update-policy":"https:\/\/doi.org\/10.1016\/elsevier_cm_policy","source":"Crossref","is-referenced-by-count":130,"title":["Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin"],"prefix":"10.1016","volume":"38","author":[{"given":"Rune","family":"Amundsen","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Hege","family":"Christensen","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Behnaz","family":"Zabihyan","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"given":"Anders","family":"\u00c5sberg","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"78","reference":[{"key":"10.1124\/dmd.110.032268_bib1","doi-asserted-by":"crossref","first-page":"648","DOI":"10.1093\/ndt\/14.3.648","article-title":"Cardiovascular morbidity and risk factors in renal transplant patients","volume":"14","author":"Aakhus","year":"1999","journal-title":"Nephrol Dial Transplant"},{"key":"10.1124\/dmd.110.032268_bib2","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1046\/j.1365-2125.1997.t01-1-00625.x","article-title":"Effect of simvastatin on cyclosporine unbound fraction and apparent blood clearance in heart transplant recipients","volume":"44","author":"Akhlaghi","year":"1997","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.110.032268_bib3","doi-asserted-by":"crossref","first-page":"615","DOI":"10.2165\/00003088-200241090-00001","article-title":"Distribution of cyclosporin in organ transplant recipients","volume":"41","author":"Akhlaghi","year":"2002","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.110.032268_bib4","doi-asserted-by":"crossref","first-page":"367","DOI":"10.2165\/00003495-200363040-00003","article-title":"Interactions between cyclosporin and lipid-lowering drugs: implications for organ transplant recipients","volume":"63","author":"Asberg","year":"2003","journal-title":"Drugs"},{"key":"10.1124\/dmd.110.032268_bib5","doi-asserted-by":"crossref","first-page":"152","DOI":"10.1097\/FTD.0b013e3181d3f822","article-title":"Computer-assisted cyclosporine dosing performs better than traditional dosing in renal transplant recipients: results of a pilot study","volume":"32","author":"Asberg","year":"2010","journal-title":"Ther Drug Monit"},{"key":"10.1124\/dmd.110.032268_bib6","doi-asserted-by":"crossref","first-page":"382","DOI":"10.1034\/j.1600-6143.2001.10415.x","article-title":"Bilateral pharmacokinetic interaction between cyclosporine A and atorvastatin in renal transplant recipients","volume":"1","author":"Asberg","year":"2001","journal-title":"Am J Transplant"},{"key":"10.1124\/dmd.110.032268_bib7","doi-asserted-by":"crossref","first-page":"1167","DOI":"10.1136\/jcp.37.10.1167","article-title":"Distribution and concentration of cyclosporin in human blood","volume":"37","author":"Atkinson","year":"1984","journal-title":"J Clin Pathol"},{"key":"10.1124\/dmd.110.032268_bib8","doi-asserted-by":"crossref","first-page":"1064","DOI":"10.1345\/aph.1E508","article-title":"Predicting inhibitory drug-drug interactions and evaluating drug interaction reports using inhibition constants","volume":"39","author":"Bachmann","year":"2005","journal-title":"Ann Pharmacother"},{"key":"10.1124\/dmd.110.032268_bib9","doi-asserted-by":"crossref","first-page":"553","DOI":"10.1001\/archinte.163.5.553","article-title":"Risk for myopathy with statin therapy in high-risk patients","volume":"163","author":"Ballantyne","year":"2003","journal-title":"Arch Intern Med"},{"key":"10.1124\/dmd.110.032268_bib10","doi-asserted-by":"crossref","first-page":"248","DOI":"10.1016\/0003-2697(76)90527-3","article-title":"A rapid and sensitive method for the quantitation of microgram quantities of protein utilizing the principle of protein-dye binding","volume":"72","author":"Bradford","year":"1976","journal-title":"Anal Biochem"},{"key":"10.1124\/dmd.110.032268_bib11","doi-asserted-by":"crossref","first-page":"537","DOI":"10.1124\/dmd.104.002477","article-title":"Differential interaction of 3-hydroxy-3-methylglutaryl-CoA reductase inhibitors with ABCB1, ABCC2, and OATP1B1","volume":"33","author":"Chen","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.032268_bib12","doi-asserted-by":"crossref","first-page":"2778","DOI":"10.1002\/jps.20733","article-title":"Prediction of plasma protein binding displacement and its implications for quantitative assessment of metabolic drug-drug interactions from in vitro data","volume":"95","author":"Christensen","year":"2006","journal-title":"J Pharm Sci"},{"key":"10.1124\/dmd.110.032268_bib13","doi-asserted-by":"crossref","first-page":"179","DOI":"10.1097\/TP.0b013e31815feede","article-title":"Declining intracellular T-lymphocyte concentration of cyclosporine A precedes acute rejection in kidney transplant recipients","volume":"85","author":"Falck","year":"2008","journal-title":"Transplantation"},{"key":"10.1124\/dmd.110.032268_bib14","doi-asserted-by":"crossref","first-page":"345","DOI":"10.1016\/j.jchromb.2007.01.039","article-title":"Determination of ciclosporin A and its six main metabolites in isolated T-lymphocytes and whole blood using liquid chromatography-tandem mass spectrometry","volume":"852","author":"Falck","year":"2007","journal-title":"J Chromatogr B Analyt Technol Biomed Life Sci"},{"key":"10.1124\/dmd.110.032268_bib15","doi-asserted-by":"crossref","first-page":"415","DOI":"10.1007\/s00210-003-0814-4","article-title":"Characterization of the transport of the bicyclic peptide phalloidin by human hepatic transport proteins","volume":"368","author":"Fehrenbach","year":"2003","journal-title":"Naunyn Schmiedebergs Arch Pharmacol"},{"key":"10.1124\/dmd.110.032268_bib16","doi-asserted-by":"crossref","first-page":"388","DOI":"10.1016\/j.clpt.2004.07.008","article-title":"Substantially elevated levels of atorvastatin and metabolites in cyclosporine-treated renal transplant recipients","volume":"76","author":"Hermann","year":"2004","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.032268_bib17","doi-asserted-by":"crossref","first-page":"1242","DOI":"10.1007\/s00216-005-3266-5","article-title":"Determination of atorvastatin and metabolites in human plasma with solid-phase extraction followed by LC-tandem MS","volume":"382","author":"Hermann","year":"2005","journal-title":"Anal Bioanal Chem"},{"key":"10.1124\/dmd.110.032268_bib18","doi-asserted-by":"crossref","first-page":"1063","DOI":"10.1007\/s11095-007-9446-6","article-title":"Multiple inhibition mechanisms and prediction of drug\u2013drug interactions: status of metabolism and transporter models as exemplified by gemfibrozil\u2013drug interactions","volume":"25","author":"Hinton","year":"2008","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.110.032268_bib19","doi-asserted-by":"crossref","first-page":"163","DOI":"10.5414\/CPP44163","article-title":"Evaluation of the pharmacokinetic interaction between fluvastatin XL and cyclosporine in renal transplant recipients","volume":"44","author":"Holdaas","year":"2006","journal-title":"Int J Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.032268_bib20","doi-asserted-by":"crossref","first-page":"473","DOI":"10.1111\/j.1365-2125.2003.02041.x","article-title":"Database analyses for the prediction of in vivo drug-drug interactions from in vitro data","volume":"57","author":"Ito","year":"2004","journal-title":"Br J Clin Pharmacol"},{"key":"10.1124\/dmd.110.032268_bib21","doi-asserted-by":"crossref","first-page":"387","DOI":"10.1016\/S0031-6997(24)01372-3","article-title":"Prediction of pharmacokinetic alterations caused by drug-drug interactions: metabolic interaction in the liver","volume":"50","author":"Ito","year":"1998","journal-title":"Pharmacol Rev"},{"key":"10.1124\/dmd.110.032268_bib22","doi-asserted-by":"crossref","first-page":"582","DOI":"10.1016\/S0002-9149(97)00965-X","article-title":"Comparative dose efficacy study of atorvastatin versus simvastatin, pravastatin, lovastatin, and fluvastatin in patients with hypercholesterolemia (the CURVES study)","volume":"81","author":"Jones","year":"1998","journal-title":"Am J Cardiol"},{"key":"10.1124\/dmd.110.032268_bib23","doi-asserted-by":"crossref","first-page":"281","DOI":"10.1016\/0009-9236(95)90153-1","article-title":"Pharmacokinetics of tacrolimus in liver transplant patients","volume":"57","author":"Jusko","year":"1995","journal-title":"Clin Pharmacol Ther"},{"key":"10.1124\/dmd.110.032268_bib24","doi-asserted-by":"crossref","first-page":"693","DOI":"10.1111\/j.1476-5381.2009.00430.x","article-title":"Impact of OATP transporters on pharmacokinetics","volume":"158","author":"Kalliokoski","year":"2009","journal-title":"Br J Pharmacol"},{"key":"10.1124\/dmd.110.032268_bib25","doi-asserted-by":"crossref","first-page":"513","DOI":"10.1097\/01.fpc.0000170913.73780.5f","article-title":"Functional characterization of SLCO1B1 (OATP-C) variants, SLCO1B1*5, SLCO1B1*15 and SLCO1B1*15+C1007G, by using transient expression systems of HeLa and HEK293 cells","volume":"15","author":"Kameyama","year":"2005","journal-title":"Pharmacogenet Genomics"},{"key":"10.1124\/dmd.110.032268_bib26","doi-asserted-by":"crossref","first-page":"365","DOI":"10.2133\/dmpk.18.365","article-title":"The intestinal first-pass metabolism of substrates of CYP3A4 and P-glycoprotein\u2014quantitative analysis based on information from the literature","volume":"18","author":"Kato","year":"2003","journal-title":"Drug Metab Pharmacokinet"},{"key":"10.1124\/dmd.110.032268_bib27","doi-asserted-by":"crossref","first-page":"1891","DOI":"10.1007\/s11095-008-9607-2","article-title":"The quantitative prediction of CYP-mediated drug interaction by physiologically based pharmacokinetic modeling","volume":"25","author":"Kato","year":"2008","journal-title":"Pharm Res"},{"key":"10.1124\/dmd.110.032268_bib28","series-title":"Drug-Drug Interactions","first-page":"123","article-title":"Drug-drug interactions involving the membrane transport process","author":"Kusuhura","year":"2002"},{"key":"10.1124\/dmd.110.032268_bib29","doi-asserted-by":"crossref","first-page":"1175","DOI":"10.1124\/dmd.105.009076","article-title":"Pharmacokinetics of atorvastatin and its hydroxy metabolites in rats and the effects of concomitant rifampicin single doses: relevance of first-pass effect from hepatic uptake transporters, and intestinal and hepatic metabolism","volume":"34","author":"Lau","year":"2006","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.032268_bib30","doi-asserted-by":"crossref","first-page":"2236","DOI":"10.1111\/j.1600-6143.2005.01005.x","article-title":"Combined therapy with atorvastatin and calcineurin inhibitors: no interactions with tacrolimus","volume":"5","author":"Lemahieu","year":"2005","journal-title":"Am J Transplant"},{"key":"10.1124\/dmd.110.032268_bib31","series-title":"High Throughput Screening: Methods and Protocols","first-page":"1","article-title":"Design and implementation of high throughput screening assays","author":"Macarr\u00f3n","year":"2002"},{"key":"10.1124\/dmd.110.032268_bib32","doi-asserted-by":"crossref","first-page":"209","DOI":"10.1248\/yakushi.127.209","article-title":"Effect of cyclosporine and tacrolimus on cytochrome P450 activities in human liver microsomes","volume":"127","author":"Niwa","year":"2007","journal-title":"Yakugaku Zasshi"},{"key":"10.1124\/dmd.110.032268_bib33","doi-asserted-by":"crossref","first-page":"434","DOI":"10.1124\/dmd.104.001909","article-title":"Role of organic anion transporter OATP1B1 (OATP-C) in hepatic uptake of irinotecan and its active metabolite, 7-ethyl-10-hydroxycamptothecin: in vitro evidence and effect of single nucleotide polymorphisms","volume":"33","author":"Nozawa","year":"2005","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.032268_bib34","doi-asserted-by":"crossref","first-page":"2049","DOI":"10.1016\/j.clinthera.2007.09.004","article-title":"Evaluation of the bioequivalence of single 100-mg doses of two oral formulations of cyclosporin A microemulsion: a randomized, open-label, two-period crossover study in healthy adult male Mexican volunteers","volume":"29","author":"Pi\u00f1eyro-L\u00f3pez","year":"2007","journal-title":"Clin Ther"},{"key":"10.1124\/dmd.110.032268_bib35","doi-asserted-by":"crossref","first-page":"59","DOI":"10.2165\/00003088-200645010-00004","article-title":"Population pharmacokinetics of tacrolimus in whole blood and plasma in Asian liver transplant patients","volume":"45","author":"Sam","year":"2006","journal-title":"Clin Pharmacokinet"},{"key":"10.1124\/dmd.110.032268_bib36","doi-asserted-by":"crossref","first-page":"1172","DOI":"10.1124\/dmd.108.025544","article-title":"Long-lasting inhibition of the transporter-mediated hepatic uptake of sulfobromophthalein by cyclosporin A in rats","volume":"37","author":"Shitara","year":"2009","journal-title":"Drug Metab Dispos"},{"key":"10.1124\/dmd.110.032268_bib37","doi-asserted-by":"crossref","first-page":"598","DOI":"10.1016\/j.healun.2009.03.014","article-title":"Conversion to tacrolimus and atorvastatin in cyclosporine-treated heart transplant recipients with dyslipidemia refractory to fluvastatin","volume":"28","author":"Skalicka","year":"2009","journal-title":"J Heart Lung Transplant"},{"key":"10.1124\/dmd.110.032268_bib38","doi-asserted-by":"crossref","first-page":"429","DOI":"10.1517\/17425255.1.3.429","article-title":"Role of the liver-specific transporters OATP1B1 and OATP1B3 in governing drug elimination","volume":"1","author":"Smith","year":"2005","journal-title":"Expert Opin Drug Metab Toxicol"},{"key":"10.1124\/dmd.110.032268_bib39","series-title":"A High-Throughput LC\/MS\/MS Method for Tacrolimus Measurement in Kidney and Liver Transplant Patients.","author":"Taylor","year":"2007"},{"key":"10.1124\/dmd.110.032268_bib40","first-page":"3944","article-title":"P-glycoprotein and cytochrome P-450 3A inhibition: dissociation of inhibitory potencies","volume":"59","author":"Wandel","year":"1999","journal-title":"Cancer Res"},{"key":"10.1124\/dmd.110.032268_bib41","doi-asserted-by":"crossref","first-page":"421","DOI":"10.1016\/S0168-3659(04)00121-X","article-title":"Bioavailability and pharmacokinetics of cyclosporine A-loaded pH-sensitive nanoparticles for oral administration","volume":"97","author":"Wang","year":"2004","journal-title":"J Control Release"},{"key":"10.1124\/dmd.110.032268_bib42","first-page":"26","article-title":"Preparation of an alternative freeze-dried pH-sensitive cyclosporine A loaded nanoparticle formulation and its pharmacokinetic profile in rats","volume":"64","author":"Yang","year":"2009","journal-title":"Pharmazie"},{"key":"10.1124\/dmd.110.032268_bib43","doi-asserted-by":"crossref","first-page":"240","DOI":"10.1002\/j.1552-4604.1987.tb02192.x","article-title":"Blood protein binding of cyclosporine in transplant patients","volume":"27","author":"Zaghloul","year":"1987","journal-title":"J Clin Pharmacol"},{"key":"10.1124\/dmd.110.032268_bib44","doi-asserted-by":"crossref","first-page":"27","DOI":"10.1016\/S1056-8719(02)00158-2","article-title":"Validation of methods to study the distribution and protein binding of tacrolimus in human blood","volume":"46","author":"Zahir","year":"2001","journal-title":"J Pharmacol Toxicol Methods"}],"container-title":["Drug Metabolism and Disposition"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024620?httpAccept=text\/xml","content-type":"text\/xml","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/api.elsevier.com\/content\/article\/PII:S0090955624024620?httpAccept=text\/plain","content-type":"text\/plain","content-version":"vor","intended-application":"text-mining"},{"URL":"https:\/\/syndication.highwire.org\/content\/doi\/10.1124\/dmd.110.032268","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2025,2,18]],"date-time":"2025-02-18T16:51:25Z","timestamp":1739897485000},"score":1,"resource":{"primary":{"URL":"https:\/\/linkinghub.elsevier.com\/retrieve\/pii\/S0090955624024620"}},"subtitle":[],"short-title":[],"issued":{"date-parts":[[2010,9]]},"references-count":44,"journal-issue":{"issue":"9","published-print":{"date-parts":[[2010,9]]}},"alternative-id":["S0090955624024620"],"URL":"https:\/\/doi.org\/10.1124\/dmd.110.032268","relation":{},"ISSN":["0090-9556"],"issn-type":[{"value":"0090-9556","type":"print"}],"subject":[],"published":{"date-parts":[[2010,9]]},"assertion":[{"value":"Elsevier","name":"publisher","label":"This article is maintained by"},{"value":"Cyclosporine A, but Not Tacrolimus, Shows Relevant Inhibition of Organic Anion-Transporting Protein 1B1-Mediated Transport of Atorvastatin","name":"articletitle","label":"Article Title"},{"value":"Drug Metabolism and Disposition","name":"journaltitle","label":"Journal Title"},{"value":"https:\/\/doi.org\/10.1124\/dmd.110.032268","name":"articlelink","label":"CrossRef DOI link to publisher maintained version"},{"value":"article","name":"content_type","label":"Content Type"},{"value":"\u00a9 2010 by The American Society for Pharmacology and Experimental Therapeutics","name":"copyright","label":"Copyright"}]}}